Seeking Alpha

Amarin (AMRN) says the FDA has not yet made a determination with respect to the regulatory...

Amarin (AMRN) says the FDA has not yet made a determination with respect to the regulatory exclusivity of Vascepa, and has not included it in its mid-August update to its Orange Book, which is due on or about September 14, 2012. Shares -2.6% AH.
Comments (6)
  • In the grand scheme of things, this may just be a really nice time to watch AMRN drop back slightly and then pick up another nice-sized block of AMRN as we watch this winner double over the coming months. Don't be that investor who missed out on this pull back! [I am long AMRN.]
    10 Sep 2012, 11:41 PM Reply Like
  • I bought 500 more shares prior to the announcement. If it drops I may pick up some more.
    11 Sep 2012, 01:45 AM Reply Like
  • Does the exclusivity matter anymore given the patents picked up recently?
    11 Sep 2012, 03:51 AM Reply Like
  • There was another patent allowance announced pre-market today. I do not believe a Sep Orange Book listing is necessarily pertinent as Amarin seems to be following a consistent plan of announcements leading up to the next quarterly filing. Feels like a well executed plan. I remain committed and will take more if price drops again without reason.
    11 Sep 2012, 04:01 AM Reply Like
  • The good news is that they did not deny the NCE.
    great early morning buying opp.
    11 Sep 2012, 06:03 AM Reply Like
  • How far do you think the price will drop before the rebound? analysts are talking in the 12 to 12.50 range.
    11 Sep 2012, 03:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)